Embecta Dirección
Dirección controles de criterios 3/4
El CEO de Embecta es Dev Kurdikar , nombrado en Apr 2022, tiene una permanencia de 4.08 años. compensación anual total es $9.40M, compuesta por 10.4% salario y 89.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.49% de las acciones de la empresa, por valor de $1.14M. La antigüedad media del equipo directivo y de la junta directiva es de 4.1 años y 4.1 años, respectivamente.
Información clave
Dev Kurdikar
Chief Executive Officer (CEO)
US$9.4m
Compensación total
| Porcentaje del salario del CEO | 10.39% |
| Permanencia del CEO | 4.1yrs |
| Participación del CEO | 0.5% |
| Permanencia media de la dirección | 4.1yrs |
| Promedio de permanencia en la Junta Directiva | 4.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización del análisis • Apr 30
EMBC: Wound Care Expansion Will Support Future Upside Despite Lower Price Targets
Analysts have trimmed their targets on Embecta by $2 to $3, citing updated expectations that align with an unchanged fair value estimate of $15, a steady discount rate of 12.33%, and consistent long term assumptions for revenue trends, profit margin, and a future P/E of about 7.9x. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed fair value estimate of $15 and implied P/E of about 7.9x as leaving room for the share price to close part of the gap if execution on the existing plan remains consistent.Actualización del análisis • Apr 15
EMBC: Higher Discount Rate And Wound Care Expansion Will Support Future Upside
Analysts have adjusted Embecta's implied fair value price target from $16.67 to $15.00, reflecting updated views on discount rates, revenue trends, profit margins and future P/E assumptions following recent research, including price target cuts from both Mizuho and BTIG. Analyst Commentary Recent research updates point to a more cautious stance on Embecta, with the lower implied fair value aligning with trimmed price targets and more conservative assumptions around growth, profitability and P/E levels.Seeking Alpha • Mar 19
Embecta: An Interesting Deal At An Interesting Time
Summary Embecta trades at multi-year lows due to GLP-1 overhang and flat sales but maintains strong margins and a >6% dividend yield. Embecta's £150M acquisition of Owen Mumford adds higher-growth exposure, is strategically sound, and is priced at a reasonable 1.4–2x sales multiple. Leverage will rise to 3.3x EBITDA post-deal but appears manageable given stable cash flows and robust profitability. I am cautiously upbeat, seeing deep value at 3x earnings, but prefer a small position due to near-term dilution and leverage concerns. Read the full article on Seeking Alpha
Actualización del análisis • Feb 18
EMBC: Future M&A And Margin Pressures Will Shape Balanced Outlook
Analysts have maintained Embecta's price target at $11.00, citing updated assumptions that include a slightly lower discount rate, softer revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Embecta is actively exploring mergers and acquisitions, with leadership emphasizing a focus on chronic care drug delivery where the company can use its manufacturing strengths and growing B2B channel (Key Developments).Artículo de análisis • Feb 12
Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively
The market seemed underwhelmed by the solid earnings posted by Embecta Corp. ( NASDAQ:EMBC ) recently. We have done...Artículo de análisis • Feb 09
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Investors in Embecta Corp. ( NASDAQ:EMBC ) had a good week, as its shares rose 2.4% to close at US$10.87 following the...Artículo de análisis • Feb 08
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 17th of...Actualización del análisis • Feb 03
EMBC: Future M&A Plans Will Test Balance Sheet And Earnings Multiple
Analysts now hold their fair value estimate for Embecta at US$11.00. The unchanged target reflects modest tweaks to assumptions around revenue growth, profit margin and future P/E that offset the slightly higher discount rate.Actualización del análisis • Jan 20
EMBC: Future M&A Ambitions Will Heighten Risk Against Weak Earnings Multiple
Analysts have kept their fair value estimate for Embecta steady at US$11.00 while slightly adjusting underlying assumptions around discount rate, revenue growth, profit margins, and forward P/E. This reflects updated views on the company’s risk profile and earnings power without a change to the headline target.Artículo de análisis • Jan 09
Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 20x, you may...Actualización del análisis • Jan 05
EMBC: Medium Term Guidance Will Balance Revenue Outlook With Margin Pressures
Analysts have modestly trimmed their price target on Embecta to 11.00 dollars, reflecting slightly higher discount rate assumptions and a marginally lower anticipated future P or E multiple, partially offset by incrementally stronger expectations for revenue growth and profit margins. What's in the News Embecta issued new fiscal 2026 guidance, projecting reported revenues between 1,071 million and 1,093 million dollars, signaling confidence in its medium term growth trajectory (Key Developments).Actualización del análisis • Dec 15
EMBC: Outlook Will Balance Stabilizing Revenues With Pressured Profit Margins Through 2026
Analysts have modestly raised their price target on Embecta to 11.00 dollars from 11.00 dollars. This reflects improved expectations for a return to positive revenue growth and a higher future earnings multiple, partially offset by a higher discount rate and slightly lower projected profit margins.Artículo de análisis • Nov 28
US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results
It's been a sad week for Embecta Corp. ( NASDAQ:EMBC ), who've watched their investment drop 14% to US$12.57 in the...Artículo de análisis • Nov 01
Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?
Embecta Corp. ( NASDAQ:EMBC ), is not the largest company out there, but it saw a significant share price rise of 36...Artículo de análisis • Sep 26
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price
Key Insights The projected fair value for Embecta is US$27.21 based on 2 Stage Free Cash Flow to Equity Embecta's...Artículo de análisis • Aug 28
Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely
Despite an already strong run, Embecta Corp. ( NASDAQ:EMBC ) shares have been powering on, with a gain of 29% in the...Actualización del análisis • Aug 10
GLP-1 Partnerships Will Expand Global Healthcare Reach
The consensus price target for Embecta has been cut from $18.33 to $16.00, primarily reflecting lowered revenue growth forecasts and a declining future P/E multiple. What's in the News Embecta Corp.Artículo de análisis • Jul 04
Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)
Embecta Corp.'s ( NASDAQ:EMBC ) price-to-earnings (or "P/E") ratio of 11.4x might make it look like a buy right now...Artículo de análisis • May 22
Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 13th of...Artículo de análisis • May 09
What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?
Embecta Corp. ( NASDAQ:EMBC ), is not the largest company out there, but it led the NASDAQGS gainers with a relatively...Artículo de análisis • Mar 06
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price
Key Insights Embecta's estimated fair value is US$24.29 based on 2 Stage Free Cash Flow to Equity Current share price...Seeking Alpha • Feb 28
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
Summary Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected to witness a headwind from increased use of pump patches in comparison to traditional insulin delivery routes. Moreover, increased GLP-1 use to treat diabetes would lead to further less frequent use of EMBC's product. However, the expanding diabetes care market should partially offset these headwinds, leading to flat topline growth in the coming years. Even though the company is going to post a flat topline, its valuation is such that the business is going to go bust in some time. This situation offers a good risk reward to go long on the stock. Read the full article on Seeking AlphaSeeking Alpha • Dec 04
New Initiatives Expected To Make Embecta More Profitable
Summary Embecta Corp.'s Q4 results showed significant net income and EPS growth as well as profitability plans, and drove up the share price. The company announced a restructuring plan to streamline operations, reduce costs by up to $65 million annually, and discontinue its insulin patch pump program. Embecta aims to strengthen its core business, expand its GLP-1 therapies portfolio, and reduce debt, positioning it for profitable growth in fiscal 2025. I have upgraded the rating on EMBC stock to a Buy, expecting a 12.0% share price increase over the next year, driven by restructuring and new revenue streams. Read the full article on Seeking AlphaArtículo de análisis • Nov 29
Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15
Embecta Corp. ( NASDAQ:EMBC ) will pay a dividend of $0.15 on the 18th of December. The dividend yield will be 2.9...Artículo de análisis • Nov 07
At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?
While Embecta Corp. ( NASDAQ:EMBC ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Artículo de análisis • Sep 24
It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
Embecta Corp.'s ( NASDAQ:EMBC ) price-to-earnings (or "P/E") ratio of 12.6x might make it look like a buy right now...
Nuevo análisis • Sep 16
Expanding Global Leadership In Insulin Devices Fuels Revenue Growth And Operational Efficiencies
Strengthening the base business in insulin injection devices suggests potential for stable, growing revenues as the global demographic needing these devices increases.Artículo de análisis • Aug 16
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 13th of...Artículo de análisis • Aug 14
Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next
Investors in Embecta Corp. ( NASDAQ:EMBC ) had a good week, as its shares rose 3.1% to close at US$14.82 following the...Artículo de análisis • Jul 13
When Should You Buy Embecta Corp. (NASDAQ:EMBC)?
While Embecta Corp. ( NASDAQ:EMBC ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Artículo de análisis • May 12
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Embecta Corp. ( NASDAQ:EMBC ) investors will be delighted, with the company turning in some strong numbers with its...Artículo de análisis • Feb 21
Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend on the 15th of March, with...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$112m |
| Dec 31 2025 | n/a | n/a | US$140m |
| Sep 30 2025 | US$9m | US$977k | US$95m |
| Jun 30 2025 | n/a | n/a | US$84m |
| Mar 31 2025 | n/a | n/a | US$53m |
| Dec 31 2024 | n/a | n/a | US$58m |
| Sep 30 2024 | US$9m | US$894k | US$78m |
| Jun 30 2024 | n/a | n/a | US$70m |
| Mar 31 2024 | n/a | n/a | US$70m |
| Dec 31 2023 | n/a | n/a | US$55m |
| Sep 30 2023 | US$7m | US$863k | US$70m |
| Jun 30 2023 | n/a | n/a | US$47m |
| Mar 31 2023 | n/a | n/a | US$94m |
| Dec 31 2022 | n/a | n/a | US$160m |
| Sep 30 2022 | US$11m | US$791k | US$224m |
| Jun 30 2022 | n/a | n/a | US$338m |
| Mar 31 2022 | n/a | n/a | US$380m |
| Dec 31 2021 | n/a | n/a | US$408m |
| Sep 30 2021 | US$3m | US$447k | US$415m |
Compensación vs. Mercado: La compensación total de Dev($USD9.40M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.59M).
Compensación vs. Ingresos: La compensación de Dev ha sido consistente con los resultados de la empresa en el último año.
CEO
Dev Kurdikar (56 yo)
4.1yrs
Permanencia
US$9,400,088
Compensación
Mr. Devdatt Kurdikar, also known as Dev, Ph.D. is an Independent Director at Zimmer Biomet Holdings, Inc since June 20, 2024. He serves as Chief Executive Officer and Director at Embecta Corp. since April...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.1yrs | US$9.40m | 0.49% $ 1.1m | |
| Senior VP & CFO | 4.1yrs | US$3.46m | 0.19% $ 446.0k | |
| Senior VP | no data | US$3.01m | 0.16% $ 372.9k | |
| Senior VP & Chief Human Resources Officer | no data | US$1.73m | 0.034% $ 79.5k | |
| Senior Vice President of Global Manufacturing & Supply Chain | no data | US$2.07m | 0.057% $ 132.9k | |
| VP, Chief Accounting Officer & Corporate Controller | 1.4yrs | sin datos | 0.080% $ 185.3k | |
| VP & Head of Investor Relations | no data | sin datos | sin datos | |
| Senior Vice President of Strategy | no data | sin datos | sin datos | |
| Senior VP & President of North America | no data | sin datos | sin datos | |
| Senior VP & President of International | no data | sin datos | sin datos |
4.1yrs
Permanencia media
53.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de EMBC se considera experimentado (4.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.1yrs | US$9.40m | 0.49% $ 1.1m | |
| Lead Independent Director | 4.1yrs | US$333.00k | 0.045% $ 104.9k | |
| Independent Director | 4.1yrs | US$331.75k | 0.056% $ 130.7k | |
| Independent Director | 4.2yrs | US$332.00k | 0.045% $ 105.0k | |
| Independent Director | 4.1yrs | US$317.00k | 0.038% $ 88.8k | |
| Independent Director | 4.1yrs | US$328.00k | 0.047% $ 109.0k | |
| Independent Director | 4.1yrs | US$317.00k | 0.045% $ 104.9k |
4.1yrs
Permanencia media
59yo
Promedio de edad
Junta con experiencia: La junta directiva de EMBC se considera experimentada (4.1 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/06 07:22 |
| Precio de las acciones al final del día | 2026/05/06 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/09/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Embecta Corp. está cubierta por 7 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |